ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 628

Urinary Heparanase Activity Is Elevated in Patients with Lupus Nephritis and Correlate with Protein Excretion

Ki-Jo Kim1, In-Woon Baek2, Chong-Hyeun Yoon3, Wan-Uk Kim2 and Chul-Soo Cho4, 1Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, 2Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 3Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, 4Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: lupus nephritis and proteinuria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: The heparin sulphate proteoglycans (HSPGs) in the glomerular basement membrane (GBM) play an important role in the charge-selective permeability of the glomerular filter. The b-D-endoglycosidase heparanase has been proposed to be important in the pathogenesis of proteinuria by selectively degrading the negatively charged side chains of HSPGs within the GBM in various forms of glomerulonephritis. We evaluated plasma and urinary activity of heparanase and determined association between its levels and proteinuria in patients with lupus nephritis.

Methods: Plasma from 86 patients with systemic lupus erythematosus (SLE) and 24 normal healthy subjects were collected. The clinical and laboratory data of the patients were obtained at the time of sampling. Forty six patients had a history of lupus nephritis and their urine was also collected. Proteinuria was defined as more than 500 mg/24h or spot urine protein/creatinine ratio > 0.5. Heparanase activity of plasma and urine was determined by a commercially available kit.

Results: Plasma heparanase activity was significantly elevated in SLE patients compared to healthy controls (734.9 ± 91.1 vs. 203.6 ± 87.1 mIU/ml, p = 0.038), but its activity was not different between patients with lupus nephritis and those without (743.3 ± 105.5 vs. 722.3 ± 166.1 mIU/ml, p = 0.915). However, urinary heparanase activity was significantly elevated in SLE patients with lupus nephritis compared to those without lupus nephritis and healthy controls (1299.7 ± 200.5 vs. 337.5 ± 35.2 and 203.6 ± 87.1 mIU/ml, p = 0.046 and 0.026, respectively). Thirty six of patients with lupus nephritis showed significant proteinuria and urinary heparanase activity of them was significantly elevated compared with those of patients without proteinuria (997.0 ± 245.3 vs. 194.6 ± 122.0 mIU/ml, p = 0.006). Importantly, urinary heparanase activity was positively correlated with protein excretion (r = 0.381, p = 0.003). Moreover, urinary heparanase activity showed an inverse correlation with C3 complement level and complement haemolytic activity (CH50) (r = -0.495, p = 0.002 and r = -0.565, p < 0.001) and had a tendency to associate negatively with C4 complement levels (r = -0.299, p = 0.072).

Conclusion: Urinary heparanase activity was elevated in patients with lupus nephritis and reflect the urinary protein excretion, suggesting a potential role in the pathogenesis of proteinuria in lupus nephritis.


Disclosure:

K. J. Kim,
None;

I. W. Baek,
None;

C. H. Yoon,
None;

W. U. Kim,
None;

C. S. Cho,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urinary-heparanase-activity-is-elevated-in-patients-with-lupus-nephritis-and-correlate-with-protein-excretion/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology